[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR072359A1 - Encapsulacion de agentes biologicamente activos - Google Patents

Encapsulacion de agentes biologicamente activos

Info

Publication number
AR072359A1
AR072359A1 ARP090101617A ARP090101617A AR072359A1 AR 072359 A1 AR072359 A1 AR 072359A1 AR P090101617 A ARP090101617 A AR P090101617A AR P090101617 A ARP090101617 A AR P090101617A AR 072359 A1 AR072359 A1 AR 072359A1
Authority
AR
Argentina
Prior art keywords
biologically active
active agent
encapsulation
aqueous
active agents
Prior art date
Application number
ARP090101617A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR072359A1 publication Critical patent/AR072359A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Composiciones que comprenden vehículos en forma de partículas que pueden obtenerse por dichos procedimientos y usos de dichas composiciones en un tratamiento. Reivindicacion 1: Un procedimiento para producir un vehículo en forma de partículas que comprende las etapas de: a) disolver polibutilcianoacrilato (PBCA) en un disolvente orgánico para formar una solucion polimérica; b) anadir una solucion acuosa que contiene un agente biologicamente activo a la solucion polimérica para formar una emulsion primaria de gotas de fase acuosa en una fase orgánica continua; c) mezclar la emulsion primaria con un medio acuoso para formar una emulsion secundaria; y d) permitir que la fase orgánica se evapore y por lo tanto obtener vehículos en forma de partículas que comprende una luz hueca que contiene el agente biologicamente activo en una fase acuosa. Reivindicacion 6: El procedimiento de una cualquiera de las reivindicaciones 1 a 4, en el que el vehículo en forma de partículas es una nanopartícula. Reivindicacion 7: El procedimiento de una cualquiera de las reivindicaciones 1 a 6, en el que el agente biologicamente activo es una proteína o péptido.
ARP090101617A 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos AR072359A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
AR072359A1 true AR072359A1 (es) 2010-08-25

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP090101619A AR072668A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101616A AR071633A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101617A AR072359A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101618A AR071634A1 (es) 2008-05-06 2009-05-05 Nanoparticulas para encapsulacion de agentes biologicamente activos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP090101619A AR072668A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101616A AR071633A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090101618A AR071634A1 (es) 2008-05-06 2009-05-05 Nanoparticulas para encapsulacion de agentes biologicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (es)
EP (2) EP2271323A2 (es)
JP (1) JP2011522792A (es)
KR (3) KR20110015604A (es)
AR (4) AR072668A1 (es)
CA (1) CA2721241A1 (es)
CL (4) CL2009001080A1 (es)
PE (4) PE20091964A1 (es)
TW (4) TW201012490A (es)
UY (4) UY31807A (es)
WO (1) WO2009135853A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064819A1 (en) * 2008-05-06 2011-03-17 Andrew Beaton Encapsulation of biologically active agents
US9504759B2 (en) 2011-08-11 2016-11-29 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
EP3148516A1 (en) * 2014-05-30 2017-04-05 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
WO2015181346A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
CA2951905A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
US10231937B2 (en) 2014-06-24 2019-03-19 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220031630A1 (en) * 2018-09-13 2022-02-03 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
WO1994017789A1 (en) * 1993-02-15 1994-08-18 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
CA2171303C (en) * 1993-09-09 2006-06-06 Werner Weitschies Active principles and gas containing microparticles
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
JP2005514326A (ja) * 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
RU2402567C2 (ru) 2003-12-05 2010-10-27 Бристоль-Майерз Сквибб Компани Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
ATE419842T1 (de) 2004-09-14 2009-01-15 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
KR101263294B1 (ko) 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト

Also Published As

Publication number Publication date
JP2011522792A (ja) 2011-08-04
US20110064821A1 (en) 2011-03-17
PE20091965A1 (es) 2010-01-09
PE20091882A1 (es) 2009-12-24
KR20110010758A (ko) 2011-02-07
CL2009001076A1 (es) 2010-09-24
AR072668A1 (es) 2010-09-15
AR071634A1 (es) 2010-06-30
WO2009135853A3 (en) 2011-05-12
CL2009001077A1 (es) 2010-09-24
CA2721241A1 (en) 2009-11-12
KR20110015604A (ko) 2011-02-16
PE20091829A1 (es) 2009-12-12
AR071633A1 (es) 2010-06-30
EP2271323A2 (en) 2011-01-12
UY31807A (es) 2009-12-14
WO2009135853A2 (en) 2009-11-12
UY31808A (es) 2009-12-14
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
EP2441447A1 (en) 2012-04-18
UY31809A (es) 2009-12-14
TW201012490A (en) 2010-04-01
KR20110010760A (ko) 2011-02-07
CL2009001080A1 (es) 2010-09-24
TW201012488A (en) 2010-04-01
CL2009001081A1 (es) 2010-09-24
UY31810A (es) 2009-12-14
TW201012489A (en) 2010-04-01

Similar Documents

Publication Publication Date Title
AR072359A1 (es) Encapsulacion de agentes biologicamente activos
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
AR092402A1 (es) Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso
BR112015010253A2 (pt) entrega de agentes biologicamente ativos com o uso de solventes hidrofóbicos e voláteis
PE20050926A1 (es) Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
GT201200069A (es) Formulaciones farmacéuticas muy concentradas
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
AR052545A1 (es) Suspension no acuosa inyectable
PE20080738A1 (es) Sistema de liberacion controlada y metodo para fabricarlo
CL2007003730A1 (es) Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.
BRPI0913326C1 (pt) formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água
CL2011002053A1 (es) Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel.
AR073801A1 (es) Emulsiones de liberacion modificadas para aplicacion en la piel o mucosa vaginal
PE20080765A1 (es) Formas de dosificacion farmaceutica
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
BRPI0518677A2 (pt) produto sàlido, processos para a produÇço de um produto sàlido e para a produÇço de uma nanodispersço estabilizada ou micela carregada, lÍquido translécido, mÉtodo de tratamento mÉdico, e, dispositivo para a produÇço de formulaÇÕes sàlidas de agentes biologicamente ativos lÍquidos
BR112015022985A2 (pt) Microesferas de buprenorfina de carga de fármaco alta e método para produção das mesmas
AR077155A1 (es) Nanodispersion, nanoparticulas y solucion
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
CO6311052A2 (es) Una microemulsion que comprende un ingrediente activo, un solvente y un surfactante no ionico y proceso para su preparación
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla
CL2010000981A1 (es) Metodo para preparar microparticulas con droga que comprende disolver un polimero biodegradable en solvente organico, disolver o dispersar una droga en la solucion, mezclar la fase de solvente droga-polimero con una suspension acuosa de gel inorganico y evaporar el solvente, recuperando las microparticulas agregando acido a la dispersion.
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
AR053023A1 (es) Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal